Bolt Biotherapeutics, Inc.

BOLT

$3.90

-2.14%

N/A-$0.09

Healthcare

Biotechnology

NASDAQ

Active Trading

Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create ...

Key Metrics of BOLT

Snapshot

Latest / TTM · 6 periods

Market Cap

$7.48M

ROCE

-90.2%

EV / EBITDA

-0.58x

-18.5% YoY

FCF Yield

-421.4%

-31.0% YoY

Cash Conversion Cycle

-1560.7d

Current Ratio

2.61

Quick take

TTM —

No major risk flags in selected headline metrics.

Key Metrics

Latest / TTM · 6 periods

Valuation trend

Valuation trend table

Metric	2021	2022	2023	2024	2025	TTM
Market CapTotal market value of all shares outstanding.	$183.26M	$48.57M	$42.35M	$20.43M	$10.23M	$7.48M
Enterprise ValueCompany value including debt and cash adjustments.	$180.23M	$61.93M	$51.76M	$38.43M	$21.48M	$16.25M
EV / SalesHow many dollars investors pay per dollar of sales.	143.04x	10.81x	6.57x	5.00x	2.79x	3.46x
EV / EBITDAValuation multiple versus operating earnings before non-cash charges.	-1.85x	-0.72x	-0.77x	-0.58x	-0.67x	-0.58x
Net Debt / EBITDALeverage ratio using net debt divided by EBITDA.	0.03	-0.15	-0.14	-0.27	-0.35	-0.32

Returns + ROCE gauge

ROCE latest

-90.2%

Prev year -71.7%

Returns + ROCE gauge table

Metric	2021	2022	2023	2024	2025	TTM
ROEProfit generated from shareholders' equity.	-39.4%	-51.4%	-61.4%	-110.4%	-125.9%	-126.2%
ROAProfit generated from total assets.	-32.0%	-38.7%	-43.3%	-63.4%	-58.8%	-71.2%
ROICReturn generated on invested operating capital.	-49.7%	-49.5%	-63.3%	-114.0%	-78.9%	-94.7%
ROCEOperating return on long-term capital used.	-32.4%	-44.1%	-54.7%	-87.2%	-71.7%	-90.2%
Earnings YieldEarnings as a percentage of market value.	-53.8%	-181.4%	-163.4%	-309.0%	-326.3%	-436.5%

Cash flow quality

Cash flow quality table

Metric	2021	2022	2023	2024	2025	TTM
FCFFCash flow available to all capital providers.	$-59.40M	$-78.46M	$-69.73M	$-61.33M	$-39.92M	$-31.54M
FCFECash flow available to equity holders after debt flows.	$-59.40M	$-78.46M	$-69.73M	$-61.33M	$-39.92M	$-31.54M
FCF YieldFree cash flow divided by market capitalization.	-32.4%	-161.5%	-164.7%	-300.2%	-390.3%	-421.4%
Income QualityHow well accounting earnings are backed by cash flow.	0.58	0.87	1.00	0.97	1.19	1.09
Capex / OCFShare of operating cash flow spent on capital expenditures.	-4.1%	-2.6%	-0.3%	-0.1%	-0.2%	-0.3%

Operating efficiency

Operating efficiency table

Metric	2021	2022	2023	2024	2025	TTM
DSOAverage days to collect cash from customers.	57.9d	0.0d	0.0d	55.3d	46.2d	0.0d
DIOAverage days inventory stays before being sold.	0.0d	0.0d	0.0d	0.0d	0.0d	0.0d
DPOAverage days the company takes to pay suppliers.	17.2d	17.9d	17.7d	0.0d	353.2d	1560.7d
Operating CycleTime from buying inventory to collecting receivables.	57.9d	0.0d	0.0d	55.3d	46.2d	0.0d
Cash Conversion CycleNet days cash is tied in operations.	40.7d	-17.9d	-17.7d	55.3d	-307.1d	-1560.7d

Snapshot

Latest / TTM: —

Market Cap

$7.48M

ROE

-126.2%

FCF Yield

-421.4%

Current Ratio

2.61

Supply Chain of BOLT

Upstream / Downstream / Proxies

Upstream

Samsung Biologics Co., Ltd.KRX:207940EirGenix, Inc.TPE:6589Piramal Healthcare UK Ltd (Piramal Pharma Ltd)NSE:PPLPHARMAToray Industries, Inc.TYO:3402

Downstream

Genmab A/SNASDAQ:GMABToray Industries, Inc.TYO:3402Innovent Biologics, Inc.HKEx:1801 Bristol Myers Squibb CompanyNYSE:BMY Roche Holding AG (F. Hoffmann-La Roche)OTC:RHHBY

Proxies

Genmab A/SNASDAQ:GMAB Samsung Biologics Co., Ltd.KRX:207940ImmunoGen (now part of AbbVie) / ADC Therapeutics SAUnconfirmed

About UsPrivacy PolicyTerms of ServiceDisclaimerStock DirectoryETFsIndices13F HoldingsAnalyst TargetsFree ToolsTechnology MapJoin our Slack

Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer